File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Self-assembly of folic acid dextran conjugates for cancer chemotherapy

TitleSelf-assembly of folic acid dextran conjugates for cancer chemotherapy
Authors
Issue Date2018
Citation
Nanoscale, 2018, v. 10, n. 36, p. 17265-17274 How to Cite?
Abstract© The Royal Society of Chemistry. Folic acid (FA) has long been used as a specific targeting agent since many cancer cells overexpress folate receptors (FRs). Herein, novel functionalities of FA will be explored: directed self-assembly of nanoparticles for drug delivery together with pH responsive release. By conjugating with dextran (DEX), DEX-FA exerts a pH dependent self-assembly behavior: it self-associates into nanoparticles (NPs) around physiological pH (pH 7) and disassembles at higher pH (pH > 9). Doxorubicin (DOX), a model antitumor drug, has been successfully encapsulated via electrostatic interactions between DOX and FA. Moreover, the pH responsive release behaviors of DOX are controlled by FA. The DOX@DEX-FA NPs exhibit typical FA-FRs-mediated endocytosis in vitro and targeted delivery in vivo, altogether contributing to an enhanced antitumor efficacy, alleviated side effects, and elongated overall survival in a 4T1 subcutaneous tumor-bearing mouse model. The DOX@DEX-FA NPs have been demonstrated to be a simple, safe and efficient nanoplatform, holding significant translation potential for treating FR-overexpressing cancers. This study may present novel functionalities of FA in cancer-targeted nanotherapeutics.
Persistent Identifierhttp://hdl.handle.net/10722/265794
ISSN
2023 Impact Factor: 5.8
2023 SCImago Journal Rankings: 1.416
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTang, Yuxiang-
dc.contributor.authorLi, Yihui-
dc.contributor.authorXu, Rong-
dc.contributor.authorLi, Si-
dc.contributor.authorHu, Hang-
dc.contributor.authorXiao, Chen-
dc.contributor.authorWu, Honglian-
dc.contributor.authorZhu, Lin-
dc.contributor.authorMing, Jiaxiong-
dc.contributor.authorChu, Zhiqin-
dc.contributor.authorXu, Huibi-
dc.contributor.authorYang, Xiangliang-
dc.contributor.authorLi, Zifu-
dc.date.accessioned2018-12-03T01:21:42Z-
dc.date.available2018-12-03T01:21:42Z-
dc.date.issued2018-
dc.identifier.citationNanoscale, 2018, v. 10, n. 36, p. 17265-17274-
dc.identifier.issn2040-3364-
dc.identifier.urihttp://hdl.handle.net/10722/265794-
dc.description.abstract© The Royal Society of Chemistry. Folic acid (FA) has long been used as a specific targeting agent since many cancer cells overexpress folate receptors (FRs). Herein, novel functionalities of FA will be explored: directed self-assembly of nanoparticles for drug delivery together with pH responsive release. By conjugating with dextran (DEX), DEX-FA exerts a pH dependent self-assembly behavior: it self-associates into nanoparticles (NPs) around physiological pH (pH 7) and disassembles at higher pH (pH > 9). Doxorubicin (DOX), a model antitumor drug, has been successfully encapsulated via electrostatic interactions between DOX and FA. Moreover, the pH responsive release behaviors of DOX are controlled by FA. The DOX@DEX-FA NPs exhibit typical FA-FRs-mediated endocytosis in vitro and targeted delivery in vivo, altogether contributing to an enhanced antitumor efficacy, alleviated side effects, and elongated overall survival in a 4T1 subcutaneous tumor-bearing mouse model. The DOX@DEX-FA NPs have been demonstrated to be a simple, safe and efficient nanoplatform, holding significant translation potential for treating FR-overexpressing cancers. This study may present novel functionalities of FA in cancer-targeted nanotherapeutics.-
dc.languageeng-
dc.relation.ispartofNanoscale-
dc.titleSelf-assembly of folic acid dextran conjugates for cancer chemotherapy-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1039/c8nr04657c-
dc.identifier.scopuseid_2-s2.0-85054003919-
dc.identifier.volume10-
dc.identifier.issue36-
dc.identifier.spage17265-
dc.identifier.epage17274-
dc.identifier.eissn2040-3372-
dc.identifier.isiWOS:000450932100036-
dc.identifier.issnl2040-3364-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats